A 60-year-old client with confirmed heparin-induced thromboc… | MyMerci
Medical EmergenciesPA
Question
A 60-year-old client with confirmed heparin-induced thrombocytopenia (HIT) has a platelet count of 38,000/μL with no active bleeding. The provider is considering platelet transfusion. Which response by the nurse demonstrates correct evidence-based knowledge?
1Prophylactic platelet transfusion should be given immediately because of the low count.
2Switch to LMWH at half dose to allow gradual platelet recovery.
3Restart UFH at a low rate to maintain stroke prevention while platelets recover.
4Platelet transfusion should generally be AVOIDED in HIT (and reserved for life-threatening bleeding only) because added platelets can fuel further IgG-PF4 mediated thrombosis; treatment focuses on stopping ALL heparin (UFH/LMWH) and starting a non-heparin anticoagulant such as argatroban or fondaparinux.✓ Correct answer
Explanation
HIT — platelet transfusion controversy HIT is paradoxically prothrombotic despite low platelet count. The mechanism (IgG antibodies to PF4-heparin) consumes circulating platelets via thrombosis, NOT bleeding. Adding platelet transfusion can fuel further antibody-mediated platelet activation and thrombosis.
Current ASH 2018 / CHEST guideline: • AVOID prophylactic platelet transfusion in HIT. • Transfusion is reserved for active major bleeding or imminent procedure with high bleeding risk. • Stop ALL heparin (UFH and LMWH — class effect, ~85% cross-reactivity) and start non-heparin anticoagulant: argatroban (preferred in renal impairment), bivalirudin, or fondaparinux. • Anti-PF4 ELISA + functional assay (SRA) for confirmation. • Avoid warfarin until platelets ≥150 K (early warfarin causes venous limb gangrene from protein C drop). • Lifetime heparin avoidance — alert band, MAR/EHR alert.
Options 3 and 4 (LMWH or UFH continuation) are both wrong because of class cross-reactivity (~85%). Option 1 (prophylactic platelet) feeds the disease.
In-depth explanation
Clinical reasoning summary HIT — platelet transfusion controversy HIT is paradoxically prothrombotic despite low platelet count. The mechanism (IgG antibodies to PF4-heparin) consumes circulating platelets via thrombosis, NOT bleeding. Adding platelet transfusion can fuel further antibody-mediated platelet activation and thrombosis.
Current ASH 2018 / CHEST guideline: • AVOID prophylactic platelet transfusion in HIT. • Transfusion is reserved for active major bleeding or imminent procedure with high bleeding risk. • Stop ALL heparin (UFH and LMWH — class effect, ~85% cross-reactivity) and start non-heparin anticoagulant: argatroban (preferred in renal impairment), bivalirudin, or fondaparinux. • Anti-PF4 ELISA + functional assay (SRA) for confirmation. • Avoid warfarin until platelets ≥150 K (early warfarin causes venous limb gangrene from protein C drop). • Lifetime heparin avoidance — alert band, MAR/EHR alert.
Options 3 and 4 (LMWH or UFH continuation) are both wrong because of class cross-reactivity (~85%). Option 1 (prophylactic platelet) feeds the disease.